Preservation of Blood in Extremely Preterm Infants (LIM)
Primary Purpose
Bronchopulmonary Dysplasia
Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Micromethods for blood sample analysis
Sponsored by
About this trial
This is an interventional prevention trial for Bronchopulmonary Dysplasia focused on measuring Extremely preterm infant, Blood sampling, Blood transfusion
Eligibility Criteria
Inclusion Criteria:
- gestational age < 27 weeks at birth
Exclusion Criteria:
- major malformation
Sites / Locations
- Neonatal Intensive Care UnitRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Micromethods for blood sample analysis
Standard clinical methods for blood sample analysis
Arm Description
Blood gases are analysed using 0.045 ml whole blood Levels of C-reactive protein (CRP) are analysed using 0.010 ml whole blood
Blood gases are analysed using 0.3 ml whole blood Levels of CRP are analysed using 0.5 ml whole blood
Outcomes
Primary Outcome Measures
Broncho-pulmonary dysplasia
Requirement of supplemental oxygen as determined by the oxygen challenge test
Secondary Outcome Measures
Cerebral intraventricular haemorrhage
Stage II, III and IV (Periventricular hemorrhagic infarction)
Necrotizing enterocolitis
Stage 2-3, Bells criteria (X-ray + clinical signs)
Blood transfusions
Administered blood transfusions (ml/kg)
Fetal Hemoglobin
% of fetal hemoglobin
Full Information
NCT ID
NCT04239690
First Posted
January 19, 2020
Last Updated
March 24, 2023
Sponsor
Lund University
Collaborators
The Swedish Research Council
1. Study Identification
Unique Protocol Identification Number
NCT04239690
Brief Title
Preservation of Blood in Extremely Preterm Infants
Acronym
LIM
Official Title
A Randomised Controlled Intervention, Multi-centre Study Aiming to Preserve Blood Factors Using Micro-methods to Improve Development in Extremely Preterm Infants - "Less is More"
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 15, 2020 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lund University
Collaborators
The Swedish Research Council
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Current clinical protocols for blood sampling and analyses in extremely preterm infants rely on an infrastructure adapted to and developed for adult medicine. Excessive blood sampling volumes and the resulting loss of fetal blood components are related to neonatal morbidity. This randomised trial aims to provide evidence that preservation of blood using micro-methods results in decreased morbidity and increased quality of life in extremely preterm infants.
Detailed Description
Extremely preterm (EPT) infants are subjected to a sample-related withdrawal of whole blood of 50 % of total blood volume during the first 2 postnatal weeks and a transfused volume of 100 % of total blood volume with donor blood during the corresponding time period. The resulting decrease in the proportion of fetal hemoglobin is strongly associated with morbidity outcome, especially broncho-pulmonary dysplasia (BPD), in the EPT infant.
This randomized trial evaluates if a reduction in sample-related blood volume loss by 50% during the first two postnatal weeks leads to a reduced rate of BPD in EPT infants. Half of the included infants will be subjected to clinical blood sampling using micromethods during the first two postnatal weeks whereas blood sampling in the other half of infants will be performed using standard clinical methods.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchopulmonary Dysplasia
Keywords
Extremely preterm infant, Blood sampling, Blood transfusion
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel assignment
Masking
Outcomes Assessor
Masking Description
Prevalence and severity of BPD at 36 weeks post-menstrual age is determined by the oxygen challenge test performed by a trained respiratory nurse blinded to treatment at each study site.
Allocation
Randomized
Enrollment
210 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Micromethods for blood sample analysis
Arm Type
Experimental
Arm Description
Blood gases are analysed using 0.045 ml whole blood Levels of C-reactive protein (CRP) are analysed using 0.010 ml whole blood
Arm Title
Standard clinical methods for blood sample analysis
Arm Type
No Intervention
Arm Description
Blood gases are analysed using 0.3 ml whole blood Levels of CRP are analysed using 0.5 ml whole blood
Intervention Type
Other
Intervention Name(s)
Micromethods for blood sample analysis
Intervention Description
Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
Primary Outcome Measure Information:
Title
Broncho-pulmonary dysplasia
Description
Requirement of supplemental oxygen as determined by the oxygen challenge test
Time Frame
Broncho-pulmonary dysplasia is determined at a postmenstrual age of 36 weeks
Secondary Outcome Measure Information:
Title
Cerebral intraventricular haemorrhage
Description
Stage II, III and IV (Periventricular hemorrhagic infarction)
Time Frame
Ultrasound at postnatal day 3, 7, 21 and 40 weeks postmenstrual age
Title
Necrotizing enterocolitis
Description
Stage 2-3, Bells criteria (X-ray + clinical signs)
Time Frame
From birth until 40 weeks postmenstrual age
Title
Blood transfusions
Description
Administered blood transfusions (ml/kg)
Time Frame
Blood transfusions administered during the first two postnatal weeks
Title
Fetal Hemoglobin
Description
% of fetal hemoglobin
Time Frame
% of fetal hemoglobin at 7 and 14 postnatal days
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
gestational age < 27 weeks at birth
Exclusion Criteria:
major malformation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David Ley, MD, PhD
Phone
+46709264524
Email
david.ley@med.lu.se
First Name & Middle Initial & Last Name or Official Title & Degree
Eva Morsing, MD, PhD
Phone
+46708788442
Email
eva.morsing@med.lu.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Ley, MD, PhD
Organizational Affiliation
Lund University, Lund, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neonatal Intensive Care Unit
City
Lund
ZIP/Postal Code
221 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Ley, MD, PhD
Phone
004646178440
Email
david.ley@med.lu.se
First Name & Middle Initial & Last Name & Degree
Eva Morsing, MD, PhD
Phone
0046178449
Email
eva.morsing@med.lu.se
12. IPD Sharing Statement
Citations:
PubMed Identifier
33547036
Citation
Hellstrom W, Martinsson T, Morsing E, Granse L, Ley D, Hellstrom A. Low fraction of fetal haemoglobin is associated with retinopathy of prematurity in the very preterm infant. Br J Ophthalmol. 2022 Jul;106(7):970-974. doi: 10.1136/bjophthalmol-2020-318293. Epub 2021 Feb 5.
Results Reference
derived
Learn more about this trial
Preservation of Blood in Extremely Preterm Infants
We'll reach out to this number within 24 hrs